Citius Pharmaceuticals : CTXR Fact Sheet
First & Only Therapies Faster to Market Upside Potential CORPORATE OVERVIEW ... | December 22, 2022
Source: marketscreener.com
📰 Alan Lader News
Alan Lader News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alan Lader. Real-time updates on events, politics, business and more.
Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
Share this article Share this article CRANFORD, N.J., April 29, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok ® Phase 3 trial-related webinar. Mino-Lok ®, the C...
Ilanit Allen Myron Holubiak Alan Lader Myron Czuczman Andrew Scott Clinical Operations At Citius Pharmaceuticals
Source: prnewswire.com
Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19
University of New Mexico VA Sierra Nevada Health Care System A few key topics on the agenda included a review of the pathogens encountered to date, the benefits of Mino-Lok for a CLABSI patient with a mucosal barrier injury, the frequency of unnecessary removal of non-colonized CVCs in suspected CLABSI patients with bacteremia, how to handle patients with multiple catheters (case history), and the path forward for study completion. "Currently, the primary treatment for patients who become bact...
Source: prnewswire.com